Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension
Objective: Evaluate long-term motor symptom control and improvement in quality of life (QoL) with foslevodopa/foscarbidopa (LDp/CDp) compared with baseline (BL) values from the parent study…One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease
Objective: To ascertain and delineate the differences in Levodopa Equivalent Dose (LEDD) among Parkinson’s disease (PD) subtypes and to examine its evolution over the disease’s…AI for Personalized Medication Management in Parkinson’s Disease
Objective: To assess medication usage over time in Parkinson’s Disease utilizing AI in EHR data. Background: Parkinson's disease (PD) is a complex neurodegenerative disorder characterized…A Comparative Bioavailability Study between a Marketed Capsule-based Levodopa Dry Powder Inhaler and a New Pre-filled Levodopa Dry Powder Inhaler
Objective: The primary objective was to determine the comparative bioavailability between a marketed and a new levodopa dry powder inhaler (DPI) with an enhanced usability…Pregnancy in Parkinson’s disease: Five cases
Objective: To report additional cases to the literature of Parkinson’s disease (PD) and pregnant. Background: Pregnancy in PD is a relatively rare occurrence as PD…Exploring Retrospectively the Predisposing Factors of Sleep Disorders in Parkinson’s Disease.
Objective: Identify the predisposing or exacerbating factors of sleep disorders in Parkinson's disease, and examine their association with levodopa treatment. Background: Parkinson's disease (PD) is…Treatment Patterns With Long-Term Foslevodopa/Foscarbidopa Use in Parkinson’s Disease
Objective: To assess long-term treatment switch patterns and discontinuation rates in patients (pts) with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp) mono- or combination therapy.…Effects of GBA mutations in patients with Parkinson’s disease and Levodopa-carbidopa intestinal gel: a nation-wide longitudinal multicentre ‘real-world’ study.
Objective: To investigate the safety and efficacy of LCIG in PD, focusing on the effects of GBA status. Background: Parkinson's disease carriers of GBA mutations/variants…Cognitive Side Effects to Initial Levodopa Exposure as a “Red Flag”: A Retrospective Study
Objective: To assess if presence of cognitive side effects during an initial levodopa trial suggests the ultimate diagnosis of atypical Parkinson (APD) vs Parkinson disease…A Post Hoc Efficacy Analysis of Phase 3 Trials of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Patients With Parkinson’s Disease
Objective: To further evaluate the efficacy of foslevodopa/foscarbidopa (LDp/CDp), a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs delivered by 24 hour/day customizable continuous subcutaneous infusion, for…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 62
- Next Page »